Objectives: To assess the clinical effectiveness, in acute ischaemic stroke patients, of bypassing non-specialist centres in preference for a specialist stroke centre to receive the time-critical intervention of thrombolysis. Methods: Systematic review and meta-analysis using: MEDLINE; MEDLINE In-Process; EMBASE; CINAHL; Cochrane Library including Cochrane Database of Systematic Reviews, Cochrane CENTRAL Controlled Trials Register, DARE, NHS EED and HTA databases. Studies were included if they compared acute ischaemic stroke patients directly triaged to a specialist centre versus those initially triaged to a non-specialist centre with some or all later transferred to a specialist centre. Studies were excluded if they compared patients ever treated in a specialist centre versus those never treated in such a centre, since the aim was to assess the optimum initial triage route rather than the optimum location for overall management. The assumption being, based on previous research, that management in a specialist centre leads to better patient outcomes. Results: Fourteen studies investigating 2790 patients were identified. Studies comparing commencement of thrombolysis in non-specialist centres versus the specialist centres (n¼1394) showed no significant difference in unadjusted mortality (OR ¼ 0.89; 95% CI ¼ 0.61-1.30) or morbidity (favourable modified Rankin Score, n ¼ 899) (OR ¼ 1.16; 95% CI ¼ 0.85-1.59) among thrombolysed patients. In studies where thrombolysis could only be administered in a specialist centre, data for patients arriving within the therapeutic window (n ¼ 140) revealed significantly higher mortality for those initially admitted to a non-specialist centre compared to directly admitted to a specialist centre (OR ¼ 6.62; 95% CI ¼ 2. 60-16.82); morbidity data also favoured direct admission to a specialist centre, although not consistently. Conclusions: For ischaemic stroke patients, the location of initial thrombolysis treatment does not affect outcomes. However, if thrombolysis is only available at a specialist centre, outcomes are considerably better for those patients admitted directly. However, these conclusions are based on poor quality data with small sample populations, significant heterogeneity and subject to confounding.
Introduction
In two reports for the Department of Health in England, the argument is made for the development of specialist stroke units to which patients are admitted directly by the ambulance service. 1, 2 The background to this is the increasing evidence of benefit from early therapy, predominantly thrombolysis, [3] [4] [5] and the coordinated care during rehabilitation that specialist units are able to provide. Outcomes from such services are consistently better than those reported for medical ward treatment. 6 In the National Institute for Health and Clinical Excellence guidelines, 7 the benefits of early management at 'acute' stroke units were supported by the expert panel consensus opinion. These guidelines concluded that all people with suspected stroke should be admitted directly to a specialist centre (SC) following initial assessment either from the community or emergency department. They also concluded that CT scans performed as early as possible provided the most costeffective management strategy. With these conclusions and evidence that thrombolysis within 90 min is better than beyond this time, 5 one option to improve outcomes may be the administration of thrombolysis in the local emergency department, prior to subsequent appropriate transfer to a regional SC.
The 2009 Cochrane review on thrombolysis 4 concluded that further trials were needed to identify the environment in which thrombolysis may best be given in routine practice. The key factor in improving outcomes in the initial phase of care appears to be the ability to deliver thrombolysis but there is conflicting evidence about where it should be delivered to achieve the best outcomes. In 2012 the Royal College of Physicians of London 8 recommended that acute stroke patients should be admitted to a specialized hyper-acute stroke unit within 1 h but accepted that 'Emergency medical staff, if appropriately trained and supported, can administer alteplase for the treatment of acute ischaemic stroke provided that patients can be managed within an acute service with appropriate neuro-radiological and stroke physician support'.
A systematic review was undertaken to assess the clinical effectiveness, in acute ischaemic stroke patients, of choosing to bypass a local non-specialist hospital in preference for a specialist stroke centre to receive the time-critical intervention of thrombolysis. Throughout this review the evidence-based assumption that care within a specialist stroke centre leads to better outcomes for stroke patients has been made.
Methods
A systematic review was undertaken according to the general principles recommended in the PRISMA statement 9 (Appendix I).
Search strategy
The following databases were searched: MEDLINE; MEDLINE In-Process; EMBASE; CINAHL; Cochrane Library including Cochrane Database of Systematic Reviews, Cochrane CENTRAL Controlled Trials Register, DARE, NHS EED and HTA databases. Searches were undertaken between August and December 2010 and updated in December 2012. An initial search was conducted and inspection of retrieved articles generated further relevant search terms that were used in an additional search. The search was limited to articles published in English from 1988 onwards, due to changes in organization of emergency care over time. (Search strategies -Appendix II).
A title and initial abstract sift were undertaken by two reviewers (SH/KC), with involvement of a third reviewer where necessary (AP). Potentially relevant articles were then fully screened by two reviewers (SH/KC) and any uncertainties resolved through discussion with a third reviewer (AP). Data were extracted by one reviewer and checked by a second.
Inclusion criteria
Patients presenting with ischaemic stroke were included because its management has a time-critical element (administration of thrombolytic therapy). 5, 10 Studies of haemorrhagic stroke were excluded since its management does not have such a clear time-critical treatment strategy. The intervention assessed was direct admission to a SC bypassing local hospitals. The comparator was initial admission to a non-specialist centre (NSC) such as a local hospital, with potential for later transfer to a SC if indicated due to the condition and severity. Studies where transfer was not possible were excluded.
Relevant outcomes included mortality and morbidity based on validated measures. The review protocol specified the outcome of mortality measured at three time points: prehospital, 7 and 30 days postevent. In a change to the protocol, due to lack of available data at the prespecified time points, mortality was included at any time point, and these data are represented in the forest plots included. The two morbidity scales used were the modified Rankin Scale (mRS) 11 and the National Institute for Health Stroke Scale (NIHSS) 12 as these were the most commonly reported in the literature. The mRS is an ordinal scale that categorizes patients from 0 (no symptoms) to 6 (dead) with 1-5 being decreasing levels of function and independence. The NIHSS scale was developed to grade stroke severity with lower scores representing less severe disease. Time to thrombolysis has been included where the data were able to be extracted.
Studies were included if they compared patients directly admitted to a SC versus those initially admitted to a NSC, with some or all later transferred. Studies were excluded if they compared patients ever versus those never treated in a SC, since the aim was to assess the optimum initial triage route rather than the optimum location for overall management. Studies where the pathway of care was uncertain were considered at full-text review and excluded if no data could be extracted to contribute to the analysis based on a consensus opinion of all reviewers.
Data synthesis
Data were meta-analysed using Review Manager version 5.0. 13 Random effects models were used where clinical or statistical heterogeneity 14 existed between studies. Clinical heterogeneity existed where studies evaluated different components of the care pathway or different patient groups within their potential cohort. Where random effects models were not used the results are presented by subgrouping similar studies. Data were converted so all odds ratios (ORs) compared initial triage to NSCs versus direct admission to SCs; similarly, ORs for survival were converted to mortality. Hence for the presented mortality data a higher OR favours direct admission to SCs, whilst for morbidity data (reporting on favourable outcomes) a lower OR favours SCs.
Risk of bias assessment
Risk of bias within included studies was assessed using criteria developed for this review, based on the Cochrane Handbook, 14 the Critical Appraisal Skills Programme checklist for cohort studies, 15 the Downs & Black checklist for study quality 16 and the Newcastle-Ottawa scale. 17 Criteria that assessed potential for bias in study design, rather than quality of reporting, were selected. No criteria are reported here relating to validity of outcome measures (since this review used prespecified, standard outcomes such as mortality and validated morbidity measures) or to blinding as the primary outcome was mortality. However, the subjective nature of the morbidity tools used would warrant an assessment of blinding and this is expanded upon in 'Results' section.
The selected criteria covered four key areas:
. Comparability between groups: risk of bias due to the lack of inclusion of, or adjustment for, NSC patients not transferred to SCs; . Adjustment: risk of bias due to lack of adjustment of analyses for differences in age and severity between groups; . Representative sample: risk of bias due to selection of patients based on condition subtype or interventions received; and . Exclusions: risk of bias due to more than 5% patients excluded due to missing data.
Results

Studies included
The review identified 14 relevant studies (15 papers). [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] (Study characteristics -Appendix III). Only controlled cohort studies were identified. Seven were conducted in the USA, 18, 20, [22] [23] [24] 28, 32 one in Taiwan 29 and five in Europe (three in Spain, 26, 27, 30 one in Germany 31 and one in France 21 ). The country was not reported in one study. 19 Two pairs of studies appeared to have overlapping cohorts. Silva et al. 22 recruited patients at the same time as Pervez et al., 20 partly in the same hospital, but for fewer years and has only been used in the synthesis where outcomes were not reported for the larger cohort in Pervez et al. 20 Similarly, Ribo et al. 27 recruited patients at the same time as Perez de la Ossa et al. 26 and from the same region, but for fewer years and has only been used in synthesis where outcomes were not reported by the latter. Study size ranged from 39 to 602 patients with a total of 2790 across all studies. SCs were described as stroke centres, stroke units or neurological units. NSCs were generally described as other hospitals or community hospitals, with some studies specifying that no specific stroke care was available.
Eleven of the included studies were restricted to patients receiving thrombolysis, therefore did not capture effects on outcomes of differing thrombolysis rates between groups, which could be affected by the initial triage decision should the transfer take patients beyond the therapeutic window. The remaining three studies were not restricted to patients receiving thrombolysis but thrombolysis was only available for transfer patients at the SC, if at all. The time to outcome assessment for both mortality and morbidity varied from inhospital to one year. These are embedded within the forest plots, listed next to each study author. Risk of bias in included studies is summarized in Appendix IV. All included studies compared patients transferred to SCs versus those directly admitted. No studies included or accounted for patients who were not transferred. Three studies adjusted at least one of their analyses for patient factors such as age and severity, while the remainder were unadjusted. The between-group difference in baseline NIHSS varied across studies, sometimes being higher in transferred patients and sometimes in patients admitted directly to specialist care (Appendix III). The number of exclusions due to missing data was unclear for four studies while the remainder appeared to have no exclusions, although it was often unclear whether only patients with available data were included.
All studies evaluated a selected subgroup of patients; none assessed all ischaemic stroke patients. Studies were subgrouped in terms of where thrombolysis was initiated for transfer patients, as described earlier.
None of the prospective studies reported any blinding of outcome assessments to the method of delivery to the SC. The other studies were all retrospective with no reported consideration of blinding.
Studies initiating thrombolysis in NSCs prior to transfer (thrombolysed patients only)
In seven studies restricted to thrombolysed patients only, transfer patients received thrombolysis in a NSC prior to transfer to a SC and were compared with patients taken directly to the SC for thrombolysis. [18] [19] [20] [21] [22] [23] 32 Two studies had a likely overlap of included patients so only the most recent is included in each analysis. 20, 22 In one other study, 50% of transfer patients received thrombolysis in the SC and 50% in the NSC. 24, 25 Four studies reported unadjusted mortality ( Figure 1 ) showing no significant difference in the individual studies or the pooled analysis for initial triage to NSC versus SC (OR 0.89, 95% CI 0.61-1.30), with no heterogeneity between studies (I 2 ¼ 0%). 18, 20, 21, 32 Another study in which transfer patients could receive thrombolysis in either the NSC or SC also showed no significant difference in mortality (OR 1.11; 95% CI 0.48-2.53). 24, 25 Five studies reported data on the proportion of patients with a favourable mRS the definition of which differed between studies, as did the time of outcome assessment ( Figure 2 ). There was no Figure 1 . Unadjusted mortality for transfer NSC to SC versus direct to SC, subgrouped by thrombolysis setting. Time of outcome measurement is shown for each study following author/date. NSC: non-specialist centre; SC: specialist centre. significant difference between groups for one study adjusting for baseline characteristics (OR 0.92; 95% CI 0.65-1.30) 20 or for four studies presenting unadjusted analyses (OR 1.16; 95% CI 0.85-1.59) ( Figure 3 ). 19, 21, 22, 32 One study reported similar reductions in mean NIHSS score at follow-up in the two groups. 23 Two studies, one in which transfer patients began thrombolysis in NSC and one in which transfer patients could receive thrombolysis in either the NSC or SC showed no significant difference between groups for the (unadjusted) proportion of patients with favourable NIHSS (score 0-5) at follow-up ( Figure 4 ). Comparisons for transfer versus direct triage to SC were OR 1.04 (95% CI 0.63-1.70) 32 and OR 1.21 (95% CI 0.67-2.19). 24, 25 Of the six studies reporting time to thrombolysis, three reported longer times in the transfer group, 20, 24, 25, 32 while three reported longer times in the direct-to-SC group (Table 1) . 19, 21, 23 
Studies initiating thrombolysis in SCs after transfer (thrombolysed patients only)
In three studies restricted to thrombolysed patients only, transfer patients began thrombolysis after transfer from NSC to SC; these were compared with patients triaged directly to the SC and receiving thrombolysis there. [26] [27] [28] Two studies had a likely overlap of included patients so only the most recent is included in each analysis. 26, 27 One study (Figure 1 ) showed no significant difference in (unadjusted) mortality for patients receiving thrombolysis after transfer versus direct triage to SC; the small number of events in this study precludes firm conclusions (OR 0.68; 95% CI 0.13-3.67). 28 One study reported data on the proportion of patients with favourable mRS. This study significantly favoured direct triage to SC when adjusting for baseline characteristics (OR 0.40; 95% CI 0.17-0.94) ( Figure 2 ) 26 and showed a non-significant trend in this direction for the unadjusted analysis (OR 0.70; 95% CI 0.35-1.41) ( Figure 3 ).
Two studies reported unadjusted data on the proportion of patients with favourable or improved NIHSS (score 0-1 or improvement of four points) at follow-up. A meta-analysis of these two studies (Figure 4 ) favoured direct triage to SC, though this was not statistically significant (OR 0.62; 95% CI 0.23-1.67). 26, 28 Two studies reported longer times from onset to thrombolysis in the transfer groups than in the directto-SC groups (Table 1) . 26, 28 Studies initiating thrombolysis in SCs after transfer (thrombolysed and non-thrombolysed patients) Three studies did not restrict recruitment to patients receiving thrombolysis. Of these, two included only patients arriving at the SC within the time window Study or Subgroup
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for thrombolysis (within 4-6 h of onset as defined by study protocol); the proportions receiving thrombolysis were 12% in one study (not reported per group) 29 with 27% for transfers and 54% for direct-to-SC in the other study. 30 The remaining study was restricted to patients with basilar artery occlusion, of whom 44% of transfers and 48% of those going direct to SC received thrombolysis. 31 In all three studies, transfer patients only received thrombolysis at the SC if at all (not at the NSC). Two studies reported (unadjusted) mortality ( Figure 1) ; both significantly favoured direct triage to SC (OR 6.62; 95% CI 2.60-16.82). 29, 31 Two studies presented data on the proportion of patients with favourable mRS again with different definitions and time of assessment. One study adjusting for baseline characteristics favoured direct triage to SC (OR 0.34; 95% CI 0.15-0.77) (Figure 2 ). 30 In unadjusted analyses, this study no longer showed a significant effect, 30 while the other study 31 significantly favoured direct triage to SC. Pooled analysis of these studies showed a non-significant trend favouring direct triage (OR 0.29; 95% CI 0.02-4.28) ( Figure 3 ).
One study presenting data on the (unadjusted) proportion of patients with favourable or improved NIHSS (score 0-1 or improvement of four points) at follow-up significantly favoured direct triage to SC (OR 0.38; 95% CI 0.20-0.74) (Figure 4 ). 30 One study reported time from onset to thrombolysis, showing a longer time in the transfer group than in the direct-to-SC group (Table 1) . 30 
Discussion
Principal findings
In studies where transfer patients were able to begin thrombolysis in a NSC prior to transfer, mortality was no different to those patients triaged directly to a SC. There was also no difference in morbidity at followup. These findings suggest that commencing thrombolysis for eligible patients in a NSC can be as effective as if delivered in a SC, within the context of the limitations identified below.
Studies in which patients only began thrombolysis after transfer from a NSC to a SC can be divided into studies restricted to thrombolysed patients only and studies assessing all patients. In both, outcomes were better for patients triaged direct to SC, statistically significant in three analyses.
Strengths and weaknesses of this study
We focused on thrombolysis, a validated treatment available with sufficient evidence to enable analysis. It is recognized that there are other interventions available and being developed for the management of acute stroke, many only available in SCs.
Only three of the 14 studies identified adjusted for age, comorbidities or severity and these were only for morbidity data. The lack of adjustment could significantly influence outcome comparisons -in particular mortality -as the lack of transfer decision randomization introduces the potential for both selection and allocation bias leading to significant differences between the NSC and SC groups. Most studies were restricted to thrombolysed patients and have not captured differences in outcome due to thrombolysis rate variability. Only one study reported these data and described a two-fold treatment rate difference, 30 which could significantly affect between-group comparison of outcomes. The higher treatment rate identified in the direct group could be considered an outcome in itself but the study does not report the 
Implications for policy
The poor quality of data identified highlights the lack of evidence to support current recommendations for direct admission of all suspected stroke patients to a SC. 8 However, the idea suggested from our results that delivery of all stroke patients to the nearest NSC is as effective as direct transfer to the SC cannot be supported. The restricted cohorts we identified limit the generalizability of our findings and, as such, must be interpreted with caution. This review found no evidence to contradict the current guidelines for the commissioning of stroke services in England. 8 
Future research
The studies identified for this review do not include a comprehensive enough cohort of patients to justify any clear conclusions, with uncertainty about the outcome for non-thrombolysed patients, the impact of triage decisions on treatment rates in appropriate patients NR NR IQR: interquartile range; NR: not reported; NSC: non-specialist centre; SC: specialist centre; SD: standard deviation; tPA: tissue plasminogen activator (thrombolysis). Definitions of study groups: A ¼ direct to SC and remained there; B ¼ to NSC initially then transferred to SC. and the relevance of the time frame for outcome assessments. When assessing the impact of an early intervention, such as triage to the most appropriate centre, the earlier the outcome is assessed the less likely that confounding can influence results. Future research should focus on a whole system approach, from the point of symptom onset, and include all suspected stroke patients managed within a network of receiving centres. In our review, seven of the 14 studies mentioned telephone and/or telemedicine contact between NSC and SC which may have facilitated the initiation of treatment prior to SC arrival. Future research should also include both short-and long-term outcomes in order to differentiate the benefit of correct triage decisions from the recognized benefits of early, focused rehabilitation and high-quality multidisciplinary care delivered in a specialist stroke centre.
